RxDoctor Payments Data

Michael Pappas, MD

Gastroenterology · Toledo, OHNPI 1437110442

Payments from drug & device makers

$14,293in general payments, 2019–2025

Across 935 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$716
  • Nestle Healthcare Nutrition Inc.$586
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$14,236100%
  • Education$570%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,293 in reported general payments places this provider in the 75th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$107,939
Medicare patients
449
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase24$139,801
ZenpepLipase/Protease/Amylase21$73,278
XifaxanRifaximin21$42,820
LinzessLinaclotide21$11,005
Mesalamine25$10,854
ZonisadeZonisamide12$10,619
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates104$6,216
Dexlansoprazole DrDexlansoprazole17$4,351
Mesalamine ErMesalamine27$3,873
Budesonide DrBudesonide17$2,959
Omeprazole222$2,688
Pantoprazole Sodium210$2,583
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl135$1,754
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl65$1,018
Esomeprazole Magnesium22$787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,619$150,80645 claims
Aimmune Therapeutics, Inc.Zenpep$285$73,27821 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,040$42,82021 claims
SandozLansoprazole$22$40014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →